Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 18 symbols : SNY save search
Global Bladder Cancer Drug Market (2021 to 2026) - Unhygienic Workplace Exposure and Increase in Smoking Habits is Driving Growth
Published: 2022-02-18 (Crawled : 21:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
bladder cancer drug work cancer drug cancer growth bladder
$26.7 Billion Adult Vaccine Market Outlook, 2027 Featuring Key Players - GSK, Merck & Co, Sanofi Pasteur, Pfizer, and CSL Limited
Published: 2022-02-18 (Crawled : 19:00) - prnewswire.com
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
| Email alert
Add to watchlist
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
| Email alert
Add to watchlist
vaccine
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
Published: 2022-02-18 (Crawled : 18:00) - globenewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
ces therapeutics
Sanofi, Regeneron Suffer Rare Dupixent Flop in CSU
Published: 2022-02-18 (Crawled : 16:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
rare dupixent
With Market Size Valued at $6.5 Billion by 2026, it`s a Healthy Outlook for the Global Throat Lozenges Market
Published: 2022-02-18 (Crawled : 16:00) - prnewswire.com
RBGPF | News | $53.94 3.53% 6.46% 3.4K
|
Consumer Non-Durables
|
| O: 3.87%
H: 0.0%
C: -3.44%
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.14%
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
RBGLY | News | $10.98 2.0% -2.05% 860K
|
Manufacturing
|
| O: 3.3%
H: 0.4%
C: -0.97%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.46%
H: 0.46%
C: -0.19%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
health
BioSpace Movers & Shakers, Feb. 18
Published: 2022-02-18 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
VXRT | News | $0.7097 -4.79% -5.72% 1.4M
|
Health Technology
|
| O: 0.0%
H: 2.95%
C: 0.21%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
BMRN | $91.2 -0.93% -0.89% 1.3M
|
Health Technology
|
| O: -1.89%
H: 1.47%
C: -4.21%
ALEC | $5.25 -1.69% -1.33% 400K
|
Health Technology
|
| O: -0.37%
H: 3.37%
C: 2.06%
space spac
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO
Published: 2022-02-18 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
als ces new ceo ceo
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
BioArctic continues to build its commercial organization
Published: 2022-02-18 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
commercialization
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.